Amneal Pharmaceuticals, Inc. (AMRX) News

Amneal Pharmaceuticals, Inc. (AMRX): $3.18

-0.28 (-8.09%)

POWR Rating

Component Grades













Filter AMRX News Items

AMRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AMRX News Highlights

  • AMRX's 30 day story count now stands at 6.
  • Over the past 26 days, the trend for AMRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • MG, ML and DRUG are the most mentioned tickers in articles about AMRX.

Latest AMRX News From Around the Web

Below are the latest news stories about Amneal Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMRX as an investment opportunity.

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 23, 2022

Amneal Expands Injectables Portfolio with 4 New Products

BRIDGEWATER, N.J., February 17, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced the approval of four generic injectables products. Dexamethasone sodium phosphate injection, USP 10 mg/mL, azacitidine 100 mg, carboprost tromethamine injection, USP 250 mcg/mL, and atropine sulfate injection, USP 0.5 mg/5 mL, have received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). Dexamethasone and azacitidine are bo

Yahoo | February 17, 2022

Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

Yahoo | February 4, 2022

Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

BRIDGEWATER, N.J., February 04, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2022.

Yahoo | February 4, 2022

Shareholders in Amneal Pharmaceuticals (NYSE:AMRX) are in the red if they invested three years ago

Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...

Yahoo | February 2, 2022

Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

Yahoo | January 28, 2022

Amneal Acquires Saol Therapeutics’ Baclofen Franchise

BRIDGEWATER, N.J. & ROSWELL, Ga., January 05, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") and Saol Therapeutics, a private specialty pharmaceutical company ("Saol"), today announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development. The acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in

Yahoo | January 5, 2022

Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., December 21, 2021--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 11:15 AM Eastern Time. A live webcast of the presentation and subsequent Q&A session will be accessible through the Investor Relations section of the Company's website at A replay of the webcast will

Yahoo | December 21, 2021

Trade Alert: The Co-Founder Of Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Chirag Patel, Has Just Spent US$626k Buying 41% More Shares

Those following along with Amneal Pharmaceuticals, Inc. ( NYSE:AMRX ) will no doubt be intrigued by the recent purchase...

Yahoo | December 19, 2021

Amneal Pharmaceuticals Inc (AMRX) Co-CEO Chintu Patel Bought $625,500 of Shares

Co-CEO of Amneal Pharmaceuticals Inc (30-Year Financial, Insider Trades) Chintu Patel (insider trades) bought 150,000 shares of AMRX on 12/16/2021 at an average price of $4.17 a share.

Yahoo | December 17, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4107 seconds.